Document is current
Any future updates will be listed below
-
Authors
Li, Rongrong
Tao, Hongyan
Pan, Kai
Li, Rui
Guo, Zhikun
Chen, Xiaoniao
Li, Zongjin https://orcid.org/0000-0002-4603-3743
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82472169)
Natural Science Foundation of Tianjin Municipal Science and Technology Commission (22JCZXJC00170)
- License Information
-
More Information
Article History
Received: 11 December 2024
Accepted: 4 March 2025
First Online: 18 March 2025
Declarations
:
: The Ethics Committee for the Use of Animals of Nankai University approved the experimental protocols for studies of mesenchymal stem cells (MSCs) for kidney injury therapy (project title: Therapeutic effects and mechanisms of mesenchymal stem cells (MSCs) for acute and chronic injury; Approval no. 20210051; Date of approval: May 20, 2021). Human placenta-derived mesenchymal stem cells (hP-MSCs) were purchased from AmCellGene Co. Ltd., Tianjin, China (). AmCellGene Co. Ltd. confirmed that there was initial ethical approval for collection of hP-MSCs, and the donors had signed informed consent.
: Not applicable.
: The authors declare that they have no competing interests.
